‘Compelling’ Data on New Agent in Pretreated Breast Cancer
Trastuzumab deruxtecan generated durable responses in HER2-positive metastatic breast cancer that had progressed on trastuzumab emtansine and other therapies in a phase 2 study. Medscape Medical News …read more